Ai Tech
OpenAI acquires Orchestra Bio
OpenAI News·October 20, 2026·1 min read
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments. Financial terms were not disclosed. The deal signals OpenAI's push into healthcare technology, where AI is increasingly used to speed clinical research and drug discovery.
Read at OpenAI NewsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.